2011-05-16T14:29:19-05:00 2010-12-31 ALEXANDER ARONSON FINNING & CO PC 21 EAST MAIN STREET WESTBORO MA 01581 990 2010-01-01 043462719 ALS THERAPY DEVELOPMENT FOUNDATION INC D/B/A ALS THERAPY DEVELOPMENT INSTITUTE ALST 6174417222 215 FIRST STREET CAMBRIDGE MA 02142 STEVE PERRIN 6174417222 2011-05-11 1 DAVID KELLEHER CPA 5083669100 2011-05-11 2010 2016-02-24 21:20:13Z STEVE PERRIN 215 FIRST STREET CAMBRIDGE MA 02142 8950469 0 1 X WWW.ALS.NET X 1999 MA ALS THERAPY DEVELOPMENT FOUNDATION IS AN INDEPENDENT NON-PROFIT BIOTECHNOLOGY RESEARCH CENTER WHICH IS AMONG THE WORLD'S LEADING TRANSLATIONAL RESEARCH PROGRAMS IN ALS, SCREENING DRUGS IN A MOUSE MODEL OF THE DISEASE. OUR MISSION IS TO IDENTIFY VIABLE TARGETS FOR THERAPY DEVELOPMENT AND EXPEDITIOUSLY MANAGE THE CREATION OF THOSE TREATMENTS THAT WILL ARREST THE SUFFERING OF TODAY'S ALS PATIENTS. 11 9 62 900 0 0 8455858 6927606 98000 0 16030 30729 343162 704819 8913050 7663154 0 0 0 0 4318795 3720298 45000 0 597891 3816363 3718935 8180158 7439233 732892 223921 4929298 5578935 661641 1087357 4267657 4491578 X OUR MISSION IS TO IDENTIFY VIABLE TARGETS FOR THERAPY DEVELOPMENT AND EXPEDITIOUSLY MANAGE THE CREATION OF THOSE TREATMENTS THAT WILL ARREST THE SUFFERING OF TODAY'S ALS PATIENTS. 0 0 6220183 ALS TDI MAINTAINED CURRENT DISCOVERY PROGRAMS TO IDENTIFY DRUGABLE TARGETS FOR ALS. WE MAINTAINED 30 DRUG DEVELOPMENT PROGRAMS AND WE RIGOROUSLY TESTED THESE POTENTIAL DRUGS IN A PRECLINICAL MODEL OF ALS. WE MAINTAINED CURRENT PROGRAMS IN THE CREATION OF IN VITRO VALIDATION, RNA VALIDATION, AND COMPUTATIONAL BIOLOGY CORES. OUR DISCOVERY RESEARCH PROGRAM MADE SIGNIFICANT PROGRESS TOWARDS UNDERSTANDING ALS AT THE GENE AND PROTEIN EXPRESSION LEVELS. AMONG OUR ACCOMPLISHMENTS WAS THE IDENTIFICATION OF THE FIRST THERAPEUTIC MODEL THAT SLOWED DOWN DISEASE PROGRESSION IN THE ALS PRECLINICAL MODEL AT ALS TDI. WE ALSO CONTINUED DEVELOPMENT OF A MASSIVE GENE TRANSCRIPTION DATABASE BASED ON A LEADING ANIMAL MODEL OF THE DISEASE AND THE IDENTIFICATION OF SPECIFIC VARIABLES WHICH COULD LEAD TO THE IMPROVED RELIABILITY OF OVERALL EXPERIMENTAL DESIGN AND FINDINGS FOR THE ENTIRE FIELD. THE PURPOSE OF THIS RESEARCH IS TO DISCOVER BIOLOGICAL MARKERS FOR THE DISEASE, TRACKING DISEASE PROGRESSION, AND TO IDENTIFY AS WELL AS VALIDATE BIOLOGICAL TARGETS FOR DRUG INTERVENTIONS. THIS WORK IS ESSENTIAL TO BOTH DIAGNOSING PATIENTS BEFORE THEY EXHIBIT SYMPTOMS OF ALS AS WELL AS FINDING TREATMENTS THAT ARREST THE PROGRESSION OF THE DISEASE TO THOSE PATIENTS. 6220183 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 30 0 1 62 1 0 0 0 0 0 0 0 0 X 11 9 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AZ CA IL IN X X X INSOURCE SERVICES INC 7812351490 148 LINDEN STREET WELLESLEY MA 02482 DR STANLEY H APPEL MD 2.50 X 0 0 0 ALEXANDER CAPPELLO 2.50 X 0 0 0 SPIROS JAMAS EDD 2.50 X 0 0 0 KEITH MELANSON 2.50 X 0 0 0 LESLIE D MICHELSON 2.50 X X 0 0 0 JOHN B HEYWOOD PHD 2.50 X 0 0 0 AUGIE NIETO 2.50 X X 0 0 0 ROB RODIN 2.50 X 0 0 0 JOHN SUTHERLAND 2.50 X 0 0 0 JAMES HEYWOOD 2.50 X 0 0 0 THEODORE REICH JD CPA 2.50 X 0 0 0 MAUREEN A LISTER 40.00 X X 237907 0 10132 STEVEN PERRIN 40.00 X X 282074 0 15117 ALAN GILL 40.00 X 137413 0 14914 JOHN LINCECUM 40.00 X 130013 0 13952 BASHAR AL-NAKHALA 40.00 X 109458 0 14793 VLADIMIR MOROZOV 40.00 X 107486 0 13835 FERNANDO VIEIRA 40.00 X 108249 0 13797 1112600 0 96540 11 0 1 0 INSOURCE SERVICES INC PO BOX 427 NEWTON UPPER FALLS MA 02464 BOOKKEEPING & FINANCE & HR & IT 311837 CAPITOL PARTNERS INC 1101 17TH STREET NW SUITE 202 WASHINGTON DC MD 20036 LEGISLATIVE SUPPORT 151935 ALLEN INSTITUTE FOR BRAIN SCIENCE 400 NORTH 34TH STREET SEATTLE WA 98103 LAB SERVICES 137779 3 1269070 1310833 4347703 59255 6927606 30729 30729 1992134 1269070 1287315 704819 704819 7663154 0 0 735548 545230 441132 61238 42860 2616151 2111654 299802 204695 28951 24894 1613 2444 312758 265388 20450 26920 217208 187373 11403 18432 31100 31100 28366 28366 50645 50645 489846 283500 65226 141120 110858 102192 2566 6100 238280 207741 5880 24659 725168 684258 13886 27024 75419 50008 1986 23425 103960 85477 2846 15637 19067 19067 329758 288590 13696 27472 TESTING AND LAB EXPENSE 1425151 1425151 MISCELLANEOUS 41298 4867 3334 33097 DUES AND SUBSCRIPTIONS 30010 24694 3901 1415 PROGRAM SUPPLIES 20009 14197 3221 2591 7439233 6220183 621159 597891 1684187 2534395 2144988 2088835 375000 115 27393 73944 185240 2085895 1397284 607790 688611 2107 4840 3512 11966 37655 37655 4929298 5578935 438240 710091 223401 377266 661641 1087357 X 3892657 4491578 375000 0 4267657 4491578 4929298 5578935 223921 X X 0 1 1 X 1 1 X 3824000 8055008 10863117 8455858 6927606 38125589 3824000 8055008 10863117 8455858 6927606 38125589 1062748 37062841 4533 47936 55426 48591 30729 187215 786134 375625 463548 310601 704819 2640727 40953531 1757753 0.90500 0.90350 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 50645 50645 7388588 7439233 521962 130491 0 0 536964 665247 559008 521962 2283181 3424772 54000 46320 45000 50645 195965 134241 166312 139752 130491 570796 856194 11389 11389 0 2069063 1380452 688611 5443 5443 0 688611 7663154 7439233 223921 0 223921 7676161 13007 13007 7663154 0 7663154 7452240 13007 13007 7439233 0 7439233 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: ALS TDI FOLLOWS THE ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES STANDARD WHICH REQUIRES ALS TDI TO REPORT UNCERTAIN TAX POSITIONS, RELATED INTEREST AND PENALTIES, AND TO ADJUST ITS ASSETS AND LIABILITIES RELATED TO UNRECOGNIZED TAX BENEFITS AND ACCRUED INTEREST AND PENALTIES ACCORDINGLY. AS OF DECEMBER 31, 2010 AND 2009, ALS TDI DETERMINED THAT THERE ARE NO MATERIAL UNRECOGNIZED TAX BENEFITS TO REPORT. TRI STATE TREK 507899 507899 76234 19429 35403 COREY REICH GALA 454791 454791 30023 4000 1594 120 2298514 1269070 1029444 1120632 3261204 1269070 1992134 106257 19429 4000 1157629 1287315 704819 X 1 1 X X X X 0 0 0 0 0 0 0 0 0 MAUREEN A LISTER 187907 0 50000 0 0 0 0 0 10132 0 248039 0 0 0 STEVEN PERRIN 282074 0 0 0 0 0 0 0 15117 0 297191 0 0 0 ALAN GILL 137413 0 0 0 0 0 0 0 14914 0 152327 0 0 0 PART I, LINE 1A THE CSO IS ALLOWED T0 FLY BUSINESS CLASS OR FIRST CLASS WHEN FLYING COAST TO COAST. X 2 608 SELLING PRICE X 9 5857 SELLING PRICE X DISCOUNTED INVOICE 17 8237 SELLING PRICE X AUCTION ITEMS 3 15558 SELLING PRICE X OTHER GOODS AND SUPPLIES 9 8204 SELLING PRICE X FUNDRAISING SUPPLIES 1 20791 SELLING PRICE 0 1 0 FORM 990, PART VI, SECTION A, LINE 2 JAMES HEYWOOD, BOARD MEMBER (AND FORMER CEO), IS THE SON OF JOHN HEYWOOD, MEMBER OF THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS REVIEWED BY THE CHIEF FINANCIAL OFFICER AND THEN APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C ALS TDI HAS A WRITTEN CONFLICT OF INEREST POLICY WHICH REQUIRES ANNUAL SIGNOFFS BY OFFICERS, DIRECTORS AND KEY EMPLOYEES. FORM 990, PART VI, SECTION B, LINE 15 THE PROCESS TO DETERMINE THE COMPENSATION OF THE PRESIDENT WAS LAST UNDERTAKEN AT THE END OF 2010 INTO EARLY 2011. THE PROCESS CONSISTED OF EVALUATING COMPARABLE DATA FOR FUNCTIONALLY SIMILAR POSITIONS AT SIMILAR ORGANIZATIONS, ALONG WITH THE REVIEW AND APPROVAL BY THE EXECUTIVE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WHICH IS COMPRISED OF INDEPENDENT MEMBERS. APPROVALS AND DISCUSSIONS WERE FORMALLY DOCUMENTED BY MEETING MINUTES FOR PRESENATION TO THE FULL BOARD FOR APPROVAL. QUESTION 15B: THE PROCESS TO ESTABLISH COMPENSATION OF OTHER OFFICERS AND KEY EMPLOYEES IS COMPLETED ON AN ANNUAL BASIS BY EVALUATING COMPARABLE DATA FOR FUNCTIONALLY SIMILAR POSITIONS AT SIMILAR ORGANIZATIONS, PRESENTING RECOMMENDATIONS TO THE EXECUTIVE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WHICH IS COMPRISED OF INDEPENDENT MEMBERS AND DOCUMENTING SUCH DISCUSSIONS IN THE BOARD MINUTES. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE ON THE ORGANIZATION'S WEB SITE. FINANCIAL STATEMENTS ARE ALSO AVAILABLE BY MAIL UPON REQUEST. FORM 990, PART XII, LINE 2C: DURING 2010, THE ORGANIZATION DID NOT CHANGE THE WAY IN WHICH ITS COMMITTEE ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT, ITS FINANCIAL STATEMENTS AND SELECTION OF AN IDEPENDENT ACCOUNTANT.